NEW YORK (GenomeWeb) – Roche announced today it has received 510(k) clearance from the US Food and Drug Administration as well as CLIA waiver for a point-of-care molecular test to detect and distinguish influenza A, influenza B, and respiratory syncytial virus.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.